What is mCRC?
In the United States, colorectal cancer (CRC) is the third leading cause of cancer-related deaths, with a projected toll of over 50,000 deaths in 2024. Overall, the lifetime risk of developing CRC is about 1 in 23 for men and 1 in 25 for women.
When people are diagnosed with later stage or more advanced CRC, it is known as metastatic CRC (mCRC).
Opens in a new window.Opens in a new window.Opens in a new window.The mCRC Survey Insights
Joined by a passion to make a difference for advanced CRC patients, Takeda and four leading advocacy organizations launched a U.S. survey to identify the most pressing needs concerning disease and treatment navigation. Through this collaborative effort, we uncovered actionable insights that helped guide the collective development of resources and education to support patients with mCRC.
[Infographic Stat]
Nearly a third of patients experienced a delay in diagnosis, with greater awareness and trustworthy informational resources being the top factors that many believe could have led to a quicker diagnosis.
[Infographic Stat]
Nearly a third of patients experienced a delay in diagnosis, with greater awareness and trustworthy informational resources being the top factors that many believe could have led to a quicker diagnosis.
[Infographic Stat]
Nearly a third of patients experienced a delay in diagnosis, with greater awareness and trustworthy informational resources being the top factors that many believe could have led to a quicker diagnosis.
[Infographic Stat]
Nearly a third of patients experienced a delay in diagnosis, with greater awareness and trustworthy informational resources being the top factors that many believe could have led to a quicker diagnosis.
